Shanghai Fosun Pharmaceutical (Group) Co., Ltd. SFOSF
Set alert
2.20 USD +0.03 +1.15%
At close · Oct 30
2.20 Day range 2.20
1.93 52-week range 3.30
- YTD
- -12.00%
- 1 year
- -33.33%
- Open
- 2.20
- Prev close
- 2.18
- Mkt cap
- 8.28B
- Vol
- 100
- Avg vol
- 112
- EPS
- 0.19
- P/E
- 11.58
More statistics
- Low
- 2.20
- High
- 2.20
- Earnings
- Aug 26, 2026
3M chart
Events in this range
- Aug 26, 2026Earnings: —; estimate 0.04162; surprise —%
Signals (19)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Overbought | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| RSI: Oversold | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 6, 2026 | 2 months ago |
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate 0.04162.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Dec 31, 2025 | 0.04162 | — | — | — |
| Apr 27, 2026 | Mar 31, 2026 | — | 0.04795 | — | — |
| Aug 26, 2025 | Jun 30, 2025 | — | 0.04907 | — | — |
| Apr 29, 2025 | Mar 31, 2025 | — | 0.03944 | — | — |
| Mar 25, 2025 | Dec 31, 2024 | — | 0.03904 | — | — |
News
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Q2 2026 Earnings Call Transcript
- Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF) Short Interest Up 21.2% in January
- Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
- Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech
- Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
- Pandemic Accelerates China's Drive Into mRNA Treatments
- Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
- Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
Your note
Sign in to keep a note on SFOSF — it syncs with the Stock Master app.